Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Column Group LLC

Q3 2023 · 13F-HR

Column Group LLCholdings as filed

Filed 2023-11-13 · accession 0000950123-23-010234

$150.6M
Reported value
7
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
75382E109RAPT Therapeutics Inc$44.6M29.6%2,680,621CommonSOLE
76155X100RVMDRevolution Medicines Inc$34.1M22.6%1,230,641CommonSOLE
87990A106TNYATenaya Therapeutics, Inc.$24.0M15.9%9,400,290CommonSOLE
68622P109ORICORIC Pharmaceuticals Inc.$21.6M14.3%3,568,181CommonSOLE
62921N105NGMUSDNGM Biopharmaceuticals Inc$19.4M12.9%18,136,735CommonSOLE
86889P109Surrozen, Inc.$4.6M3.06%9,414,795CommonSOLE
28202V108eFFECTOR Therapeutics Inc$2.4M1.60%4,026,224CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.